APO Research
Talk to an analyst

APO RESEARCH · REPORT

Candidiasis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Candidiasis Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchCandidiasis Therapeutics Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Candidiasis Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Candidiasis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Candidiasis Therapeutics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Candidiasis Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Candidiasis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Candidiasis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Candidiasis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Candidiasis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Candidiasis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Candidiasis Therapeutics market include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer-Algeta, Amgen, Merrion Pharmaceuticals Plc., Medivir AB, Genta Incorporated, Galapagos NV and Digna Biotech S.L., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Candidiasis Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Candidiasis Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Candidiasis Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Candidiasis Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Candidiasis Therapeutics Segment by Company

Novartis AG

F. Hoffmann-La Roche Ltd.

Bayer-Algeta

Amgen

Merrion Pharmaceuticals Plc.

Medivir AB

Genta Incorporated

Galapagos NV

Digna Biotech S.L.

Catena Pharmaceuticals Inc.

Amura Holdings

Ablynx

Candidiasis Therapeutics Segment by Type

Vincristine

Ifosfamide

Etoposide

Cisplatin

Methotrexate

Cyclophosphamide

Doxorubicin

7Carboplatin

Candidiasis Therapeutics Segment by Application

Multispecialty Hospitals

Cancer Research Institutes

Others

Candidiasis Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Candidiasis Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Candidiasis Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Candidiasis Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Candidiasis Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Candidiasis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Candidiasis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Candidiasis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Candidiasis Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Candidiasis Therapeutics industry.

Chapter 3: Detailed analysis of Candidiasis Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Candidiasis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Candidiasis Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Candidiasis Therapeutics Industry Trends Table 2. Candidiasis Therapeutics Industry Drivers Table 3. Candidiasis Therapeutics Industry Opportunities and Challenges Table 4. Candidiasis Therapeutics Industry Restraints Table 5. Global Candidiasis Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Candidiasis Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Candidiasis Therapeutics Sales Volume by Company (k units) & (2021-2026) Table 8. Global Candidiasis Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Candidiasis Therapeutics Average Price (US$/unit) of Company (2021-2026) Table 10. Global Candidiasis Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Candidiasis Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Candidiasis Therapeutics Company, Product Type & Application Table 13. Global Candidiasis Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Candidiasis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vincristine Table 18. Significant Companies of Ifosfamide Table 19. Significant Companies of Etoposide Table 20. Significant Companies of Cisplatin Table 21. Significant Companies of Methotrexate Table 22. Significant Companies of Cyclophosphamide Table 23. Significant Companies of Doxorubicin Table 24. Significant Companies of 7Carboplatin Table 25. Global Candidiasis Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Candidiasis Therapeutics Sales Volume by Type (2021-2026) & (k units) Table 27. Global Candidiasis Therapeutics Sales Volume by Type (2027-2032) & (k units) Table 28. Global Candidiasis Therapeutics Sales Volume Share by Type (2021-2026) Table 29. Global Candidiasis Therapeutics Sales Volume Share by Type (2027-2032) Table 30. Global Candidiasis Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Candidiasis Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Candidiasis Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Candidiasis Therapeutics Sales Value Share by Type (2021-2026) Table 34. Global Candidiasis Therapeutics Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Multispecialty Hospitals Table 36. Significant Companies of Cancer Research Institutes Table 37. Significant Companies of Others Table 38. Global Candidiasis Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Candidiasis Therapeutics Sales Volume by Application (2021-2026) & (k units) Table 40. Global Candidiasis Therapeutics Sales Volume by Application (2027-2032) & (k units) Table 41. Global Candidiasis Therapeutics Sales Volume Share by Application (2021-2026) Table 42. Global Candidiasis Therapeutics Sales Volume Share by Application (2027-2032) Table 43. Global Candidiasis Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Candidiasis Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Candidiasis Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Candidiasis Therapeutics Sales Value Share by Application (2021-2026) Table 47. Global Candidiasis Therapeutics Sales Value Share by Application (2027-2032) Table 48. Global Candidiasis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 49. Global Candidiasis Therapeutics Sales by Region (2021-2026) & (k units) Table 50. Global Candidiasis Therapeutics Sales Market Share by Region (2021-2026) Table 51. Global Candidiasis Therapeutics Sales by Region (2027-2032) & (k units) Table 52. Global Candidiasis Therapeutics Sales Market Share by Region (2027-2032) Table 53. Global Candidiasis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Candidiasis Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Candidiasis Therapeutics Sales Value Share by Region (2021-2026) Table 56. Global Candidiasis Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Candidiasis Therapeutics Sales Value Share by Region (2027-2032) Table 58. Global Candidiasis Therapeutics Market Average Price (US$/unit) by Region (2021-2026) Table 59. Global Candidiasis Therapeutics Market Average Price (US$/unit) by Region (2027-2032) Table 60. Global Candidiasis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 61. Global Candidiasis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Candidiasis Therapeutics Sales by Country (2021-2026) & (k units) Table 63. Global Candidiasis Therapeutics Sales Market Share by Country (2021-2026) Table 64. Global Candidiasis Therapeutics Sales by Country (2027-2032) & (k units) Table 65. Global Candidiasis Therapeutics Sales Market Share by Country (2027-2032) Table 66. Global Candidiasis Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Candidiasis Therapeutics Sales Value Market Share by Country (2021-2026) Table 68. Global Candidiasis Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Candidiasis Therapeutics Sales Value Market Share by Country (2027-2032) Table 70. Novartis AG Company Information Table 71. Novartis AG Business Overview Table 72. Novartis AG Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Novartis AG Candidiasis Therapeutics Product Portfolio Table 74. Novartis AG Recent Development Table 75. F. Hoffmann-La Roche Ltd. Company Information Table 76. F. Hoffmann-La Roche Ltd. Business Overview Table 77. F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Product Portfolio Table 79. F. Hoffmann-La Roche Ltd. Recent Development Table 80. Bayer-Algeta Company Information Table 81. Bayer-Algeta Business Overview Table 82. Bayer-Algeta Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Bayer-Algeta Candidiasis Therapeutics Product Portfolio Table 84. Bayer-Algeta Recent Development Table 85. Amgen Company Information Table 86. Amgen Business Overview Table 87. Amgen Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Amgen Candidiasis Therapeutics Product Portfolio Table 89. Amgen Recent Development Table 90. Merrion Pharmaceuticals Plc. Company Information Table 91. Merrion Pharmaceuticals Plc. Business Overview Table 92. Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Product Portfolio Table 94. Merrion Pharmaceuticals Plc. Recent Development Table 95. Medivir AB Company Information Table 96. Medivir AB Business Overview Table 97. Medivir AB Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Medivir AB Candidiasis Therapeutics Product Portfolio Table 99. Medivir AB Recent Development Table 100. Genta Incorporated Company Information Table 101. Genta Incorporated Business Overview Table 102. Genta Incorporated Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Genta Incorporated Candidiasis Therapeutics Product Portfolio Table 104. Genta Incorporated Recent Development Table 105. Galapagos NV Company Information Table 106. Galapagos NV Business Overview Table 107. Galapagos NV Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Galapagos NV Candidiasis Therapeutics Product Portfolio Table 109. Galapagos NV Recent Development Table 110. Digna Biotech S.L. Company Information Table 111. Digna Biotech S.L. Business Overview Table 112. Digna Biotech S.L. Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Digna Biotech S.L. Candidiasis Therapeutics Product Portfolio Table 114. Digna Biotech S.L. Recent Development Table 115. Catena Pharmaceuticals Inc. Company Information Table 116. Catena Pharmaceuticals Inc. Business Overview Table 117. Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Catena Pharmaceuticals Inc. Candidiasis Therapeutics Product Portfolio Table 119. Catena Pharmaceuticals Inc. Recent Development Table 120. Amura Holdings Company Information Table 121. Amura Holdings Business Overview Table 122. Amura Holdings Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Amura Holdings Candidiasis Therapeutics Product Portfolio Table 124. Amura Holdings Recent Development Table 125. Ablynx Company Information Table 126. Ablynx Business Overview Table 127. Ablynx Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Ablynx Candidiasis Therapeutics Product Portfolio Table 129. Ablynx Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Candidiasis Therapeutics Distributors List Table 133. Candidiasis Therapeutics Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Candidiasis Therapeutics Product Image Figure 2. Global Candidiasis Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Candidiasis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Candidiasis Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Candidiasis Therapeutics Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Candidiasis Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vincristine Image Figure 10. Ifosfamide Image Figure 11. Etoposide Image Figure 12. Cisplatin Image Figure 13. Methotrexate Image Figure 14. Cyclophosphamide Image Figure 15. Doxorubicin Image Figure 16. 7Carboplatin Image Figure 17. Global Candidiasis Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Candidiasis Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Candidiasis Therapeutics Sales Volume Share by Type (2021-2032) Figure 20. Global Candidiasis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Candidiasis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Candidiasis Therapeutics Sales Value Share by Type (2021-2032) Figure 23. Multispecialty Hospitals Image Figure 24. Cancer Research Institutes Image Figure 25. Others Image Figure 26. Global Candidiasis Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Candidiasis Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Candidiasis Therapeutics Sales Volume Share by Application (2021-2032) Figure 29. Global Candidiasis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Candidiasis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Candidiasis Therapeutics Sales Value Share by Application (2021-2032) Figure 32. Global Candidiasis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 33. Global Candidiasis Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Candidiasis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Candidiasis Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Candidiasis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. North America Candidiasis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Candidiasis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Candidiasis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Candidiasis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Candidiasis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Candidiasis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 43. South America Candidiasis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Candidiasis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Candidiasis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Candidiasis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Candidiasis Therapeutics Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Candidiasis Therapeutics Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Vincristine
  • Ifosfamide
  • Etoposide
  • Cisplatin
  • Methotrexate
  • Cyclophosphamide
  • Doxorubicin
  • 7Carboplatin
Applications
  • Multispecialty Hospitals
  • Cancer Research Institutes
  • Others
Companies covered
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Bayer-Algeta
  • Amgen
  • Merrion Pharmaceuticals Plc.
  • Medivir AB
  • Genta Incorporated
  • Galapagos NV
  • Digna Biotech S.L.
  • Catena Pharmaceuticals Inc.
  • Amura Holdings
  • Ablynx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Candidiasis Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Candidiasis Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Candidiasis Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Candidiasis Therapeutics Market Dynamics
  1. 2.1 Candidiasis Therapeutics Industry Trends
  2. 2.2 Candidiasis Therapeutics Industry Drivers
  3. 2.3 Candidiasis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Candidiasis Therapeutics Industry Restraints
3 Candidiasis Therapeutics Market by Company
  1. 3.1 Global Candidiasis Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Candidiasis Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Candidiasis Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Candidiasis Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Candidiasis Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Candidiasis Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Candidiasis Therapeutics Company Product Type and Application
  8. 3.8 Global Candidiasis Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Candidiasis Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Candidiasis Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Candidiasis Therapeutics Market by Type
  1. 4.1 Candidiasis Therapeutics Type Introduction
  2. 4.1.1 Vincristine
  3. 4.1.2 Ifosfamide
  4. 4.1.3 Etoposide
  5. 4.1.4 Cisplatin
  6. 4.1.5 Methotrexate
  7. 4.1.6 Cyclophosphamide
  8. 4.1.7 Doxorubicin
  9. 4.1.8 7Carboplatin
  10. 4.2 Global Candidiasis Therapeutics Sales Volume by Type
  11. 4.2.1 Global Candidiasis Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Candidiasis Therapeutics Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Candidiasis Therapeutics Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Candidiasis Therapeutics Sales Value by Type
  15. 4.3.1 Global Candidiasis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Candidiasis Therapeutics Sales Value by Type (2021-2032)
  17. 4.3.3 Global Candidiasis Therapeutics Sales Value Share by Type (2021-2032)
5 Candidiasis Therapeutics Market by Application
  1. 5.1 Candidiasis Therapeutics Application Introduction
  2. 5.1.1 Multispecialty Hospitals
  3. 5.1.2 Cancer Research Institutes
  4. 5.1.3 Others
  5. 5.2 Global Candidiasis Therapeutics Sales Volume by Application
  6. 5.2.1 Global Candidiasis Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Candidiasis Therapeutics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Candidiasis Therapeutics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Candidiasis Therapeutics Sales Value by Application
  10. 5.3.1 Global Candidiasis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Candidiasis Therapeutics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Candidiasis Therapeutics Sales Value Share by Application (2021-2032)
6 Candidiasis Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Candidiasis Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Candidiasis Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Candidiasis Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Candidiasis Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Candidiasis Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Candidiasis Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Candidiasis Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Candidiasis Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Candidiasis Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Candidiasis Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Candidiasis Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Candidiasis Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Candidiasis Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Candidiasis Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Candidiasis Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Candidiasis Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Candidiasis Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Candidiasis Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Candidiasis Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Candidiasis Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Candidiasis Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Candidiasis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Candidiasis Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Candidiasis Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Candidiasis Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Candidiasis Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Candidiasis Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Candidiasis Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Candidiasis Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Candidiasis Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Candidiasis Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Candidiasis Therapeutics Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 F. Hoffmann-La Roche Ltd.
  8. 8.2.1 F. Hoffmann-La Roche Ltd. Company Information
  9. 8.2.2 F. Hoffmann-La Roche Ltd. Business Overview
  10. 8.2.3 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Product Portfolio
  12. 8.2.5 F. Hoffmann-La Roche Ltd. Recent Developments
  13. 8.3 Bayer-Algeta
  14. 8.3.1 Bayer-Algeta Company Information
  15. 8.3.2 Bayer-Algeta Business Overview
  16. 8.3.3 Bayer-Algeta Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bayer-Algeta Candidiasis Therapeutics Product Portfolio
  18. 8.3.5 Bayer-Algeta Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Candidiasis Therapeutics Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 Merrion Pharmaceuticals Plc.
  26. 8.5.1 Merrion Pharmaceuticals Plc. Company Information
  27. 8.5.2 Merrion Pharmaceuticals Plc. Business Overview
  28. 8.5.3 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Product Portfolio
  30. 8.5.5 Merrion Pharmaceuticals Plc. Recent Developments
  31. 8.6 Medivir AB
  32. 8.6.1 Medivir AB Company Information
  33. 8.6.2 Medivir AB Business Overview
  34. 8.6.3 Medivir AB Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Medivir AB Candidiasis Therapeutics Product Portfolio
  36. 8.6.5 Medivir AB Recent Developments
  37. 8.7 Genta Incorporated
  38. 8.7.1 Genta Incorporated Company Information
  39. 8.7.2 Genta Incorporated Business Overview
  40. 8.7.3 Genta Incorporated Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Genta Incorporated Candidiasis Therapeutics Product Portfolio
  42. 8.7.5 Genta Incorporated Recent Developments
  43. 8.8 Galapagos NV
  44. 8.8.1 Galapagos NV Company Information
  45. 8.8.2 Galapagos NV Business Overview
  46. 8.8.3 Galapagos NV Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Galapagos NV Candidiasis Therapeutics Product Portfolio
  48. 8.8.5 Galapagos NV Recent Developments
  49. 8.9 Digna Biotech S.L.
  50. 8.9.1 Digna Biotech S.L. Company Information
  51. 8.9.2 Digna Biotech S.L. Business Overview
  52. 8.9.3 Digna Biotech S.L. Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Digna Biotech S.L. Candidiasis Therapeutics Product Portfolio
  54. 8.9.5 Digna Biotech S.L. Recent Developments
  55. 8.10 Catena Pharmaceuticals Inc.
  56. 8.10.1 Catena Pharmaceuticals Inc. Company Information
  57. 8.10.2 Catena Pharmaceuticals Inc. Business Overview
  58. 8.10.3 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Product Portfolio
  60. 8.10.5 Catena Pharmaceuticals Inc. Recent Developments
  61. 8.11 Amura Holdings
  62. 8.11.1 Amura Holdings Company Information
  63. 8.11.2 Amura Holdings Business Overview
  64. 8.11.3 Amura Holdings Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amura Holdings Candidiasis Therapeutics Product Portfolio
  66. 8.11.5 Amura Holdings Recent Developments
  67. 8.12 Ablynx
  68. 8.12.1 Ablynx Company Information
  69. 8.12.2 Ablynx Business Overview
  70. 8.12.3 Ablynx Candidiasis Therapeutics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Ablynx Candidiasis Therapeutics Product Portfolio
  72. 8.12.5 Ablynx Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Candidiasis Therapeutics Value Chain Analysis
  2. 9.1.1 Candidiasis Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Candidiasis Therapeutics Sales Mode & Process
  6. 9.2 Candidiasis Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Candidiasis Therapeutics Distributors
  9. 9.2.3 Candidiasis Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst